早在今年3月，百健和卫材公司曾宣布，将终止对“aducanumab”药物的两项后期试验，因为当时一项分析显示，他们成功研制出治疗阿尔茨海默综合症药物的希望十分渺茫。当时，这两家公司的股价一路大跌。

The announcement is somewhat surprising because the company had discontinued work on the drug in March 2019, after disappointing trial results.

　　

       2019年3月21日，百健公司关于停止aducanumab用于治疗阿尔茨海默症试验的公告

　　不过，该公司称，新的数据显示，加大剂量对于治疗阿尔茨海默症早期症状，有显著效果，可以减缓患者记忆力衰退、遗忘日常生活技能等症状。

　　But the company says a new analysis of a larger dataset of the same studies shows that higher doses of aducanumab can provide a significant benefit to patients with early Alzheimer's, slowing their clinical decline so they preserve more of their memory and every day living skills - things that the disease usually robs.

　　根据最新试验分析，该公司“复活”了aducanumab。

The company resurrected the drug after additional analyses suggested it might have some effect at higher doses.

　　百健此次宣布药物的消息令市场十分兴奋。据报道，22日，百健公司的股票价格飙升27%，卫材公司的股价上涨了18%。几乎收回了3月份放弃这两项研究时的损失。

　　

CNBC对此事的报道视频截图The drugmaker's shares soared 27% in New York trading, recouping almost all of the $18 billion it lost when it said in March it was abandoning the two studies. Shares in Eisai Co, Biogen's Japanese partner in the drug, were quoted up 18% to the daily limit high of 6,534 yen in Tokyo trading.这家制药公司的股价在纽约市场上飙升了27%，几乎收回了3月份宣布放弃这两项研究时损失的180亿美元。百健公司的日本合作伙伴卫材的股票在东京市场中上涨了18%，达到6534日元的日最高限额。▌外媒：上市批准尚无保证，仍需谨慎看待

　　对于这一消息，《纽约时报》直言，不能高兴太早（it is not quite time for these patients to celebrate）。

　　文章指出，该公司还没有公布最新分析数据，效果究竟如何还不得而知。目前看，只是能延缓阿尔茨海默症患者的一些认知衰退症状。

　　The company has not published the most recent analyses, and experts are mostly in the dark as to how well the drug works. It neither prevents nor cures Alzheimer's; the company claims only that aducanumab may slow cognitive decline in some patients.

　　该公司尚未公布最新分析数据，专家们大多数并不知道该药物效果如何。它不是预防或治愈阿尔茨海默症。公司只是说aducanumab可能会延缓某些患者的认知衰退症状。